Because monotherapy activity has been identified as a key predictor of clinical benefit for combination treatments,30 the monotherapy activity of vidutolimod demonstrated in this study may be the most important evidence of differentiation from other agents evaluated as immunotherapy combination partners in PD‐1 blockade–resistant, advanced nonocular melanoma. This evidence concerns the gene PDCD1 and melanoma.